Peripheral neuropathy in patients with gynecologic cancer receiving chemotherapy: patient reports and provider assessments.
OBJECTIVE
To analyze the incidence of chemotherapy-induced neuropathy in a set of patients with gynecologic cancer who were treated with known neurotoxic agents, to identify correlative factors related to patients' experience of neuropathy, and to analyze providers' assessment and treatment of neuropathy.


METHODS
Observational descriptive study of patient-reported neuropathy using a retrospective chart analysis.


METHODS
A hospital-based outpatient infusion center in the southeastern United States.


METHODS
A convenience sample of 171 patients with gynecologic cancer for a total of 302 chemotherapy treatments.


METHODS
A mixed model and compound symmetry covariance matrix was used to adjust for correlations between neuropathy treatment scores and patients who completed more than one chemotherapy cycle. Backward elimination method was used to determine the final model.


METHODS
Functional Assessment of Cancer Treatment/Gynecologic Oncology Group-Neuropathy Treatment scores, patients' demographic information, past medical history, and chemotherapy history.


RESULTS
Patients who were physically shorter and heavier than the average population had the highest rating of neuropathy. Patients who were treated with nontaxane and platinum therapies had less neuropathy than patients who were treated with first-line taxanes and platinums. Neuropathy was noted by providers early in the course of treatment, and providers' grading was consistent with the patients' scoring.


CONCLUSIONS
First-line treatments for gynecologic malignancies resulted in the highest neuropathy scores; however, patients who had received previous treatment with taxane and platinum therapies had lower neuropathy scores than patients currently receiving taxanes and platinums, suggesting that neuropathy improved after completion of first-line therapy and that second-line therapies were not necessarily correlative with worsening scores.


CONCLUSIONS
Nurses must educate patients about symptoms of neuropathy and the need to report symptoms. Nurses must recognize patients at highest risk for neuropathy and advocate use of validated assessment tools.
Gynecologic Oncology Department, Blumenthal Cancer Center, Charlotte, NC, USA. deleslie.kiser@carolinashealthcare.org
Deleslie W
DW
Kiser
Tara B
TB
Greer
Margaret C
MC
Wilmoth
Jacek
J
Dmochowski
R Wendel
RW
Naumann
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000009:adverse effects*; D005260:Female; D005833:Genital Neoplasms, Female / Q000188:drug therapy / Q000451:nursing / Q000523:psychology; D006801:Humans; D008875:Middle Aged; D009498:Neurotoxins / Q000009:adverse effects; D009730:Nursing Assessment; D009859:Oncology Nursing / Q000379:methods*; D010353:Patient Education as Topic / Q000379:methods; D010523:Peripheral Nervous System Diseases / Q000139:chemically induced / Q000451:nursing / Q000523:psychology; D010984:Platinum / Q000009:adverse effects; D012189:Retrospective Studies; D043823:Taxoids / Q000009:adverse effects; D055815:Young Adult
D000970:Antineoplastic Agents; D009498:Neurotoxins; D043823:Taxoids; D010984:Platinum